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ReviewAbstract
Pathologic increase in bone marrow reticulin fibrosis can be present in many malignant
hematopoietic diseases. In acute leukemia, one-third of patients have some degree of marrow
reticulin fibrosis at presentation, which is thought to be related to cytokine release from blasts.
Marrow fibrosis is particularly common in acute megakaryoblastic leukemia, while this change is
rarely seen in acute promyelocytic leukemia. Six case reports of acute promyelocytic leukemia
with marrow reticulin fibrosis have been described so far in the literature. Herein, we present
three cases of classical acute promyelocytic leukemia with increased marrow reticulin fibrosis
encountered in our institution, summarizing their clinicopathologic features, treatment, and
outcome to date. Awareness of the features of acute promyelocytic leukemia with marrow reti-
culin fibrosis is important as it may guide treatment options.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Pathologic increase in bone marrow reticulin fibrosis can be
seen in numerous malignant conditions [1]. In acute
leukemia, around one-third of patients have some degreeescription
2 I. Abou Dalle et al.of marrow reticulin fibrosis (MRF) at presentation. The
increase in reticulin fibers in the marrow has been attribu-
ted to cytokine overproduction by leukemic cells expressing
CD34 and HLA-DR [2]. The degree and occurrence of MRF
vary significantly depending on the subtype of leukemia,
with acute megakaryoblastic leukemia commonly showing
an increase in marrow reticulin fibers, while acute promye-
locytic leukemia (APL) rarely presenting with increased MRF
[3,4]. To date, six cases of APL with MRF (APL-MRF) have
been described in the literature. We herein present three
cases of APL-MRF encountered at our institution over the
course of 2 years, and we summarize their clinicopathologic
features, treatment, and outcome, with a review of rele-
vant literature.Case presentations
Patient 1
The patient was a 28-year-old female who initially pre-
sented to an outside medical center with palpitations, head-
ache, and dizziness. Peripheral blood counts showed a
hemoglobin level of 8.9 g/dL, a platelet count of
122  109/L, and a leukocyte count of 2.1  109/L. Physical
examination was essentially unremarkable. Her diagnostic
work-up included flow cytometry immunophenotyping per-
formed on peripheral blood that showed no evidence ofFig. 1 Patient 1. Suboptimal bone marrow core biopsy at initial d
of morphology, showing a diffuse population of atypical cells with
200) and (B) increased reticulin fibrosis (reticulin special stain,
(1 month after diagnosis) with no evidence of acute leukemia, b
hyperplasia (hematoxylin and eosin, 200) and (D) increased reticu
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remarkable for severe reticulin fibrosis with no increase in
blasts. The patient received blood transfusions and
granulocyte-colony stimulating factor injections for
3 months without improvement in peripheral blood indices.
She was then referred to our institution for further manage-
ment. The outside bone marrow core biopsy was reviewed in
our pathology department and showed an increase in imma-
ture cells with eosinophilic cytoplasm and with increased
reticulin fibrosis (Fig. 1A and B). The atypical cells were dif-
fusely positive for myeloperoxidase by immunohistochem-
istry, but negative for CD34. A repeat bone marrow
aspirate was hypocellular but showed 55% blasts having
hypergranular cytoplasm and numerous Auer rods, with
‘‘faggot cells” being identified. Real-time polymerase chain
reaction (RT-PCR) analysis performed on the bone marrow
aspirate for promyelocytic leukemia – retinoic acid
receptor-alpha (PML-RARA) fusion transcript was positive
with a normalized copy number of 3,063. Mutations in
Jak2 and MPL genes were not detected. The overall findings
were consistent with APL-MRF. The patient was subse-
quently started on arsenic trioxide (ATO) 0.15 mg/kg daily
and all-trans retinoic acid (ATRA) 45 mg/m2 daily. Post
induction, a repeat bone marrow aspirate still yielded a
dry tap, but a repeat bone marrow core biopsy showed a
hypercellular marrow with atypical megakaryocytic hyper-
plasia and increased reticulin fibrosis (Fig. 1C and D). A
repeat RT-PCR for PML-RARA after induction therapy withiagnosis (received for consultation), with marginal preservation
(A) moderate eosinophilic cytoplasm (hematoxylin and eosin,
100). Follow-up bone marrow core biopsy after treatment
ut with (C) increased cellularity and atypical megakaryocytic
lin fibrosis (reticulin special stain, 200).
c leukemia with increased bone marrow reticulin fibrosis: Description
her (2016), http://dx.doi.org/10.1016/j.hemonc.2016.08.001
Acute promyelocytic leukemia with bone marrow fibrosis 3ATO and ATRA was low positive with a normalized copy
number of 62. The patient is currently receiving consolida-
tion treatment.
Patient 2
The patient was a 24-year-old previously healthy man who
presented for excessive bleeding after tooth extraction
and easy bruising. His peripheral blood counts showed
hyperleukocytosis with a white blood cell count of
37.3  109/L and 80% blasts, a hemoglobin level of
11.7 g/dL, and a platelet count of 75  109/L. Other
laboratory values showed evidence of mild disseminated
intravascular coagulation. A bone marrow aspirate showed
numerous hypergranular blasts, many having Auer rods, with
occasional ‘‘faggot cells.” By flow cytometry immunopheno-
typing performed on the marrow aspirate, the blasts were
positive for CD13 and CD33, and negative for CD34,
CD117, HLA-DR, and lymphoid and monocytic markers. A
bone marrow core biopsy showed a diffuse infiltrate of
granular immature-looking cells with a severe increase inFig. 2 Patient 2. Bone marrow core biopsy at diagnosis showin
eosinophilic granular cytoplasm (hematoxylin and eosin, 200) and
bone marrow biopsy after treatment (2 months after diagnosis) sho
for age with trilineage hematopoiesis (hematoxylin and eosin, 100
stain, 100). Repeat bone marrow biopsy (8 months after diagnos
cellularity (hematoxylin and eosin, 100) and (F) no increase in re
(12 months) showing normal cellularity (G) with trilineage hematopo
in reticulin fibrosis (reticulin stain, 200).
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was positive, and an FLT3 D835 point mutation was also
detected. The overall findings were consistent with
APL-MRF. The patient was then treated with idarubicin
and ATRA. Follow-up bone marrow aspirate postinduction
showed no evidence of leukemia, and a repeat core biopsy
after first consolidation showed no evidence of residual
acute leukemia, with a decrease in marrow reticulin to
MF-1. Subsequent core biopsies after completion of treat-
ment showed no evidence of MRF (MF-0; Fig. 2C–F). Addi-
tionally, molecular remission was achieved after
consolidation treatment. Approximately 12 months after
the initial diagnosis, a repeat bone marrow core biopsy
showed no evidence of acute leukemia; however, there
was reappearance of mild and focal reticulin fibrosis
(Fig. 2G and H). Molecular testing at that time was negative
for PML-RARA. Three months later, a bone marrow aspirate
showed relapsed APL with similar features to the patient’s
original disease. He was then treated with ATO and ATRA
as salvage therapy, and again went into morphologic and
molecular remission after consolidation. A bone marrowg a diffuse population of immature cells with (A) moderate
(B) increased reticulin fibrosis (reticulin stain, 100). Follow-up
wing no evidence of acute leukemia, (C) a hypocellular marrow
), and (D) focal residual increase in reticulin fibrosis (reticulin
is) showing no evidence of acute leukemia, with (E) improving
ticulin fibrosis (reticulin stain, 100). Follow-up bone marrow
iesis (hematoxylin and eosin, 200), but (H) with focal increase
c leukemia with increased bone marrow reticulin fibrosis: Description
her (2016), http://dx.doi.org/10.1016/j.hemonc.2016.08.001
4 I. Abou Dalle et al.biopsy was not repeated after salvage therapy. The patient
refused autologous hematopoietic cell transplantation and
was lost to follow-up.
Patient 3
The patient was a 42-year-old previously healthy female
who presented for easy bruising and heavy menses. Periph-
eral blood counts showed a hemoglobin level of 6.4 g/dL, a
platelet count of 26  109/L, and a leukocyte count of
0.8  109/L. Peripheral smears showed no significant mor-
phologic abnormalities. A bone marrow aspirate yielded a
dry tap, whereas the touch preparation of the core biopsy
showed numerous blasts having irregular and occasionally
bilobed nuclei, open chromatin, prominent nucleoli, and
hypergranular cytoplasm. Additionally, occasional Auer rods
and rare ‘‘faggot cells” were seen. By immunohistochemical
staining performed on the bone marrow core biopsy, the
blasts were diffusely positive for myeloperoxidase and
CD117, and showed partial expression of CD34. The reticulin
stain showed a moderate increase in reticulin fibrosis
(MF-2). RT-PCR performed on a peripheral blood sample
detected PML-RARA fusion transcript with a normalized
copy number of 121024. The patient was thus started on
ATO and ATRA, and achieved molecular remission after
the first consolidation. Follow-up bone marrow aspirates
showed no evidence of acute leukemia; however, repeat
bone marrow core biopsies were not performed. After
1 year of her diagnosis, the patient’s peripheral blood
counts have been within normal range.
Discussion
Structural fibrils in the bone marrow are an essential part of
the physiologic microenvironment composition, acting as a
support for hematopoietic cells to survive and proliferate
[11]. Bone marrow is composed of two major types of fibers:
reticulin and collagen I/III. Reticulin fibrosis is often rever-
sible, whereas collagen deposition is persistent.
The pathophysiology of increased bone marrow fibrosis is
incompletely understood and is thought to be a reactive
process in response to increased hematopoietic activity.
Recently, an increase in the number of megakrayocytes
and platelets, often morphologically atypical, was observed
in most disorders associated with marrow fibrosis, mainly in
acute megakaryoblastic leukemia and primary myelofibrosis
[12,13]. Cytokine release from megakaryocytes and plate-
lets seems to promote fibroblast proliferation and collagen
synthesis [11]. Platelet-derived growth factor enhances
fibroblast growth, and transforming growth factor b1 stimu-
lates fibroblast collagen synthesis. Other fibroblast growth
factors and tissue inhibitors of matrix metalloproteinases
are also implicated [13–15]. However, in disorders where
no abnormal megakaryocytes are observed, leukemic cells
expressing CD34 and HLA-DR may have a major contribution
to the cytokine network and reticulin synthesis. It is still
unclear why fibrosis and cytokine overproduction are much
less seen in APL compared with other subtypes of acute
myeloid leukemia. One can hypothesize that the frequent
lack of CD34 and HLA-DR expression in APL accounts for
the uncommon increase in reticulin fibrosis in this entity.Please cite this article in press as: Abou Dalle I et al., Acute promyelocyti
of three cases and review of the literature ..., Hematol Oncol Stem Cell THowever, this was not the situation in our patients who
had typical features of APL, without CD34 expression,
except for Patient #3 in whom partial CD34 expression was
noted.
Following a PubMed search, six case reports of APL-MRF
were found in the literature. A summary of these reports is
presented in Table 1. Among the six reported cases, three
had blasts with CD34 and HLA-DR expression. Mori et al. [9]
suggested a role of transforming growth factor b1 among
other fibrogenic cytokines in the fibrillogenesis in APL as they
noticed its overexpression, by RT-PCR, in their reported case.
Interestingly, transforming growth factor b1was also overex-
pressed in cases of hairy cell leukemia [16], further implicat-
ing this cytokine in the development of marrow fibrosis. Of
note, Patient #1 reported herein showed a hypercellularmar-
row with atypical megakaryocytic hyperplasia with marrow
fibrosis on a follow-up bone marrow core biopsy, raising the
possibility of an underlying myeloproliferative neoplasm.
However, no molecular support for myeloproliferative neo-
plasm was found. These findings are unusual in APL cases
and their significance remains unclear.
The clinical relevance of increased reticulin fibrosis is
still not well elucidated. Some reports correlated severity
of marrow fibrosis with a worse prognosis. The presence
of collagen deposition was associated with worse survival
in primary myelofibrosis and was shown to be predictive of
response in chronic myelogenous leukemia after allogeneic
stem cell transplantation [17,18]. In myelodysplastic syn-
dromes, patients with moderate to severe fibrosis have sig-
nificantly worse survival than patients with no evidence of
marrow fibrosis [19]. Based on a limited number of reports,
patients diagnosed with APL with marrow fibrosis seem to
respond well to ATRA-containing therapeutic regimens,
which is similar to what is seen in cases of nonfibrotic
APL. Furthermore, the combination of ATO and ATRA was
well tolerated by our patients. By contrast, bone marrow
fibrosis in acute leukemia historically raised concerns about
delayed marrow recovery after chemotherapy. However, a
study by Islam et al. [3] which included 34 patients with
acute myeloid leukemia, demonstrated that normal marrow
recovery was achieved after myelosuppressive treatment
despite the presence of severe fibrosis. All reported cases,
including ours, experienced timely marrow recovery as well
as lengthy molecular remission despite marrow fibrosis at
initial presentation. Usually, fibrotic marrow is reversible
after treatment [3,4], but this process is gradual and may
not be seen until further consolidation treatment and
achievement of continuous complete remission. None of
the patients reported above had complete resolution of
bone marrow reticulin fibrosis after induction treatment.
However, among the previously reported patients for whom
a follow-up bone marrow biopsy was available after consol-
idation treatment, three had evidence of resolution of mar-
row fibrosis [6,8,9].
Of note, fibrosis can reappear at relapse [4]. We have
noticed in our second patient the reappearance of reticulin
fibrosis around 1 year after initial diagnosis, and after the
patient had achieved complete morphologic and molecular
remission with resolution of fibrosis. Interestingly, the reap-
pearing reticulin fibrosis was seen before relapse, suggest-
ing that recurrent fibrosis might represent an early sign of
relapse, warranting closer patient monitoring.c leukemia with increased bone marrow reticulin fibrosis: Description
her (2016), http://dx.doi.org/10.1016/j.hemonc.2016.08.001
Table 1 Summary of baseline characteristics, treatment, and outcomes of our patients along with the other reported six patients with acute promyelocytic leukemia and
marrow fibrosis.
Author/country Age (y)/sex Presentation Morphology Treatment Response Follow-up
Patient 1 28/F Pancytopenia Blasts with Auer rods,
hypergranular promyelocytes,
severe reticulin fibrosis
ATO + ATRA Morphologic complete
remission
2 mo
Persistent fibrosis
postinduction
Patient 2 24/M Bleeding Blasts with Auer rods, severe
reticulin fibrosis
Idarubicin + ATRA Molecular CR Relapse 15 mo later
then lost of FUResolution of fibrosis
at the end of treatment
Patient 3 42/F Pancytopenia Blasts hypergranular with rare
Auer rods, mild expression of
CD34, presence of reticulin
fibrosis
ATO + ATRA Molecular CR 1 y
No FU on fibrosis
Shah et al. [5]/USA 48/M Pancytopenia Blasts with Auer rods, rare
promyelocytes, severe reticulin
fibrosis
Idarubicin + ATRA Molecular CR 4 y
Persistent fibrosis
postinduction
No FU on fibrosis
Lu et al. [6]/China 34/F Pancytopenia Blasts CD34 + HLA-DR + severe
fibrosis
ATO + ATRA Molecular CR 3 y
DIC Resolution of fibrosis
Dutta et al. [7]/India 25/M Bleeding Abnormal granular promyelocytes Daunorubicin + ATRA Molecular CR NA
Mild DIC Persistent fibrosis
postinduction
Fukuno et al. [8]/Japan 18/M DIC Atypical morphology, blasts CD34
+ HLA-DR + diffuse fibrosis
Daunorubicin Molecular CR 21 mo
Enocitabine
6-MP s/p AutoBMT
ATRA Resolution of fibrosis
Mori et al. [9]/Japan 26/M Pancytopenia Diffuse reticulin fibrosis with few
hematopoietic cells
Daunorubicin Resolution of fibrosis after
consolidation
Relapse after 2 y
DIC Enocitabine
ATRA
Aventin et al. [10]/Spain 22/F Easy bruising Atypical morphology, blasts CD34
+ HLA-DR + severe fibrosis
Chemotherapy Molecular CR 12 mo
ATRA No FU on fibrosis
Note. ATO = arsenic trioxide; ATRA = all-trans retinoic acid; AutoBMT = autologous bone marrow transplantation; CR = complete remission; DIC = disseminated intravascular coagulopathy;
F = female; FU = follow-up; M = male; NA = not available; 6-MP = 6-mercaptopurine; s/p: status post.
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6 I. Abou Dalle et al.Conclusion
The frequency of bone marrow fibrosis in APL is unknown
because bone marrow biopsies are not routinely performed
in such cases. However, its incidence is still considered very
low. The presence of marrow fibrosis in APL can pose a diag-
nostic challenge to clinicians, falsely lowering the level of
suspicion for this neoplasm and possibly causing a delay in
the administration of adequate therapy. Therefore, it is
important for practicing hematologists and hematopatholo-
gists to be aware of the possibility of marrow fibrosis in APL,
since a correct diagnosis of APL with early incorporation of
ATRA can offer a better chance for cure.
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